Next Article in Journal
Pathogenesis, Diagnosis, and Management of Trigeminal Neuralgia: A Narrative Review
Previous Article in Journal
Genetic Risk Profiling Reveals Altered Glycosyltransferase Expression as a Predictor for Patient Outcome in Neuroblastoma
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Naegleria fowleri Infections: Bridging Clinical Observations and Epidemiological Insights

by
Carmen Rîpă
1,2,
Roxana Gabriela Cobzaru
1,2,*,
Miruna Raluca Rîpă
3,
Alexandra Maștaleru
4,5,
Andra Oancea
4,5,
Carmen Marinela Cumpăt
5,6 and
Maria Magdalena Leon
4,5
1
Department of Microbiology, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”, Universitatii Street No. 16, 700115 Iasi, Romania
2
Department of Preventive Medicine and Interdisciplinarity, University of Medicine and Pharmacy “Grigore T. Popa”, Universitatii Street No. 16, 700115 Iasi, Romania
3
University of Medicine and Pharmacy “Grigore T. Popa”, Universitătii Street No. 16, 700115 Iasi, Romania
4
Department of Medical Specialties I, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania
5
Clinical Rehabilitation Hospital, 700661 Iasi, Romania
6
Department of Medical Specialties III, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(2), 526; https://doi.org/10.3390/jcm14020526
Submission received: 19 December 2024 / Revised: 5 January 2025 / Accepted: 13 January 2025 / Published: 15 January 2025
(This article belongs to the Section Infectious Diseases)

Abstract

:
Purpose: Naegleria fowleri is the main etiologic agent implicated in primary amoebic meningoencephalitis (PAM). It is also known as the brain-eating amoeba because of the severe brain inflammation following infection, with a survival rate of about 5%. This review aims to identify Naegleria fowleri infections and evaluate patients’ progression. This literature review emphasizes the importance of rapid diagnosis and treatment of infected patients because only prompt initiation of appropriate therapy can lead to medical success. Compared to other articles of this kind, this one analyzes a large number of reported cases and all the factors that affected patients’ evolution. Materials and methods: Two independent reviewers used “Naegleria fowleri” and “case report” as keywords in the Clarivate Analytics—Web of Science literature review, obtaining 163 results. The first evaluation step was article title analysis. The two reviewers determined if the title was relevant to the topic. The first stage removed 34 articles, leaving 129 for the second stage. Full-text articles were evaluated after reading the abstract, and 77 were eliminated. This literature review concluded with 52 articles. Key findings: This review included 52 case report articles, 17 from the USA, eight from India, seven from China, four from Pakistan, two from the UK, and one each from Thailand, Korea, Japan, Italy, Iran, Norway, Turkey, Costa Rica, Zambia, Australia, Taiwan, and Venezuela, and Mexico. This study included 98 patients, with 17 women (17.4%) and 81 men (82.6%). The cases presented in this study show that waiting to start treatment until a diagnosis is confirmed can lead to rapid worsening and bad outcomes, especially since there is currently no drug that works very well as a treatment and the death rate is around 98%. Limitations: The lack of case presentation standardization may lead to incomplete case information in the review since the cases did not follow a writing protocol. The small number of global cases may also lead to misleading generalizations, especially about these patients’ treatment. Due to the small number of cases, there is no uniform sample of patients, making it difficult to determine the exact cause of infection.

1. Introduction

Naegleria fowleri is the main etiologic agent implicated in primary amoebic meningoencephalitis (PAM) [1]. It is also known as the brain-eating amoeba because of the severe inflammation of the brain following infection, with a survival rate of about 5% [2]. It is most commonly found in water or wet soils and grows very well on cell cultures or various artificial media [1]. Temperatures above 30 °C create a favorable environment for this amoeba, with survival and infection being impossible in the winter season [3]. However, it is not only high temperatures that can be a favorable factor but also the increased amount of suspended organic matter and sediment, which lead to poor water quality and a favorable environment for the development of amoebae [4]. This is the only amoeba species exhibiting three distinct morphologic forms: the trophozoite, flagellate, and cyst [1,5]. Naegleria fowleri enters the host’s system via the nasal tract, either by inhalation of dust-containing cysts or by aspiration of water contaminated with trophozoites or cysts. Young people are most often affected, as they are most often exposed to potentially contaminated environments [6]. The clinical course is mostly dramatic, and after an incubation period of 2 to 15 days, the disease has a sudden onset with a fulminant course toward death [7]. Since the officially recorded case of onset, contrary to the evolution of medicine, the number of cases seems to be increasing, with 381 cases reported from 1962 to 2018, originating in 33 countries [3,8]. Between 1965 and 2016, the overall number of reported PAM cases grew by 1.6% every year. During this time, the number of confirmed PAM cases grew by an average of 4.5% yearly [9]. In a 2020 study, it was reported that the worldwide prevalence of Naegleria in various water sources was 26.42%. The highest case rate was found in America, approximately 33.18%, not only due to multiple sources for possible infection, but also due to the large number of studies that have taken place in this territory [10].
This review aims to identify documented cases of Naegleria fowleri infection and analyze the evolution of patients since the time of infection. Thus, through this literature review, we want to emphasize the importance of the rapid diagnosis and treatment of infected patients since only the initiation of appropriate therapy as promptly as possible can lead to medical success. Compared to other articles of this sort, this one brings together a large number of reported cases, analyzing in detail all the aspects that had an impact on the evolution of patients infected with Naegleria fowleri.

2. Materials and Methods

The literature review was performed by two independent reviewers on the Clarivate Analytics—Web of Science platform using as keywords the association between “Naegleria fowleri” and “case report” and 163 results were obtained. The first evaluation step was to analyze the title of the articles. If the title was considered significant for the chosen topic, the two reviewers proceeded to abstract analysis. After the first stage, 34 articles were eliminated, leaving 129 articles for the second stage. After reading the abstract, the next eliminatory stage was the evaluation of full-text articles, and 77 papers were excluded. Finally, 52 articles were included in this literature review.
The inclusion criteria were English language, and case report type articles describing the cases of patients infected with Naegleria fowleri, regardless of the evolution they had after confirmation of the diagnosis. All eligible articles were included regardless of the year of publication or the age of patients included in the studies.
Exclusion criteria were articles that were written in full-text in a language other than English, articles that could not be accessed, conference presentations, abstracts, letters to the editor, books, editorial material, proceeding papers or review articles, and articles in which insufficient patient data were identified.

3. Results

The general characteristics of the cases included in our study can be observed in Table 1.
The evolution and treatment of the patients included in this review can be observed in Table 2.
This review included 52 case report articles, 17 from the USA, eight from India, seven from China, four from Pakistan, two from the UK, and one each from Thailand, Korea, Japan, Italy, Iran, Norway, Turkey, Costa Rica, Zambia, Australia, Taiwan, Venezuela, and Mexico. A total of 99 patients were included, including 17 women (17.17%) and 82 men (82.82%). (Figure 1)
The patients’ ages in the study ranged from 11 days to 75 years. There were seven patients less than 1 year old, 16 patients aged between 2 and 10 years, 19 patients aged between 10 and 20 years, 13 patients aged between 21 and 40 years, and 12 patients older than 40 years. In addition, in two of the studies mentioned in the review, there were 19 and 13 patients, respectively, with a mean age of 28 and 31 ± 15.33 years, respectively. Approximately, the age at which patients are more susceptible to Naegleria fowleri infection seems to be 10–40 years.
Discussing the way of infection, in 40 of the 99 cases, no exact cause or contact with contaminated water could be established, and in only one person, no link between infection and a water source was observed. Five of the patients developed symptoms after playing in areas with contaminated water, seven after swimming in pools that were irrigated with spring water, and eight and six, respectively, after swimming in lakes or rivers. One of the patients under the age of 1 died shortly after baptism, and another after being exposed to water collected after rain. For five people, symptoms started after bathing in possibly contaminated water, and six after swimming in areas where Naegleria fowleri was found after water testing. The condition of four of the patients worsened after nasal irrigation with tap water, and of another four after using tap water for various household activities. Other sources of infection were ditch water, canal irrigation, water tanks, or water parks (Figure 2).
The most common symptoms with which patients in the articles included in the review presented to the doctor were fever, headache, and vomiting, symptoms specific for meningeal inflammation. Other less common symptoms were seizures, neck stiffness, fatigue, confusion, and sensory disturbances. In most cases, no exact diagnosis was considered until the results were received. However, patients who presented with symptoms specific to meningeal irritation were given a presumptive diagnosis of viral or bacterial meningitis.
Of the 99 patients, only 11 of them survived the Naegleria fowleri infection, the mortality rate being 88.88%. (Figure 3) The hospitalization period ranged from 10 h to 4 months. Further discussion on the hospitalization period shows that the most common hospitalization period was 1–5 days (45 patients). Six patients were hospitalized for 5–10 days, 3 for 1–15 days, and 14 for more than 15 days. In one study, the hospitalization period of 13 patients was approximately 6.38 ± 3.15 days. Only one case, a 6-month-old infant, had a fulminant progression to death within 10 h.
Of the patients who survived, the average age was 17.8 years and the average length of hospitalization was 29.5 days. Excluding the only elderly patient in this group (73 years), the mean age for surviving patients was 11.66 years, with a mean number of days hospitalized of 31.67. In terms of patients who did not survive, the average age was about 21 years, with a number of days of hospitalization of around 8.39 days. If we exclude the only patient who was hospitalized for 4 months, the average number of days of hospitalization becomes about 6.25 days. Thus, we could say that the patients who were cured had a much longer period of hospitalization, but also a lower average age, compared to those who did not survive the Naegleria fowleri infection.

4. Discussion

4.1. Prevention

Infection with Naegleria fowleri is often fatal, with death occurring in less than 72 h in many patients [50]. As observed in the cases included in this study, it seems that one of the most common causes of infection is contact with contaminated water. Most of the time, patients come in contact with water by swimming in lakes, rivers, or even swimming pools that are not properly sanitized [59]. With modernization, the number of cases among tourists who frequent vacation resorts that include heated swimming pools has increased. For example, a 2005 study evaluating the presence of this amoeba in tourist sites in Thailand found that Naegleria fowleri was present in about 40% of the recreational sites sampled [60]. Infection can only be prevented by avoiding these types of recreational areas because, as observed in the cases presented above, most of the hospitalized patients had a history of swimming either in unsanitized swimming ponds or in natural recreational sites such as lakes or rivers. Another method of prevention could be to avoid swallowing or mouth or nostril contact with contaminated water [43].
In the cases presented above, some of the patients came into contact with this amoeba after nasal irrigation with contaminated water; therefore, people practicing this habit should be more careful about the water they use because the olfactory mucosa is one of the entry points of the amoeba [40]. When it comes to cases of infection in newborns, parents should be cautious about the water they use for preparing milk and bathing their babies since they cannot become contaminated by swimming in potentially infectious areas, but only by contact with contaminated water through ingestion or during bathing [51]. For this reason, the diagnosis of PAM is very difficult to consider in this type of patient, thus lowering the success rate of therapy [51]. Among the six cases of children under 1 year of age included in the review, four of them mention contaminated water in which the babies were being bathed as the cause of infection.
Those most susceptible to infection with this amoeba are young people with good immunity, especially young men because they are most often involved in water recreational activities in the warm season [21,31]. As noted in our review, the average hospitalization period until patients most often progress to fatality is about 5–10 days from the onset of symptoms [31]. However the infection rate is quite low, and the incidence of the disease is very low, because rarely do people who come in contact with a potential source of infection develop the disease [47].

4.2. Diagnosis

For patients to have a favorable outcome, therapy should be started as soon as possible; for this reason, physicians should be much better informed about this infection and its signs and take it into account when patients are presented in the emergency room [22]. PAM is clinically indistinguishable from classic bacterial meningitis, which is why the amoebic etiology should be suspected whenever the presence of a pathogenic bacterium cannot be detected in the CSF. Criteria that could guide the physician toward the diagnosis of this infection could be young age, recent activity in the aquatic environment, or contact with various water sources, especially heated swimming pools, rivers, lakes, or stagnant water [3,7,31]. Even when considering possible Naegleria infection, delaying optimal medication until the diagnosis is confirmed is not an ideal option, as trophozoites in cerebrospinal fluid are detected by time-consuming methods. In most of the presented cases, patients became comatose by the time of diagnostic confirmation and under correct therapy they decompensated [47]. The methods of choice for diagnosis are evaluation of the CSF smear and brain biopsy, but in recent years, there have been studies that have shown the efficiency and rapidity of next-generation sequencing (NGS) [58]. Even so, if the Naegleria fowleri infection is not taken into account and therapy is not initiated until the results are received, the chances of survival decrease, especially as there is currently no drug with substantial therapeutic efficacy, the mortality rate being approximately 98% [55].

4.3. Treatment

Regarding treatment, active substances proven to be useful include Amphotericin B, Miconazole, Tetracycline, and Rifampicin. The drug of choice used to treat this infection is Amphotericin B, administered intravenously and intrathecally, thus ensuring an increased concentration in the cerebrospinal fluid [4]. Lately, an antiparasitic called Miltefosine has been added to the basic therapeutic regimen, together with Amphotericin B, Rifampicin, and Fluconazole, with an increased success rate [56,57]. This was validated as a therapy in 2022 after an 8-year-old child was completely cured after it was added to the therapeutic regimen. Even though Amphotericin B has proven its efficacy, the similar adverse effects with patients’ onset symptoms plus nephrotoxicity emphasize the need for a new therapy. Moreover, Miltefosine has proven to be effective when it comes to patient survival following Naegleria fowleri infection, but in most cases, patients are neurologically affected [61].
Recently, there has been increasing discussion about new nanoparticle-based therapies, which are superior to older drugs because they can cross the blood–brain barrier much more easily, without the need for an additional dose increase [61,62]. Studies show that a large amount of the drug could be administered intranasally via these nanoparticles, but the cytotoxic effects and pharmacokinetics are not fully known [63]. For example, in 2017, a study of a silver nanoparticle conjugated with Amphotericin B, Nystatin, and Fluconazole was reported, which showed in vitro efficacy against the brain-eating amoeba but showed a cytotoxic effect of up to 75% [64]. On the other hand, the 50 µM concentration of a gold nanoparticle conjugated with trans-cinnamic acid showed efficacy as high as Amphotericin B, with no signs of cell toxicity [65].

5. Conclusions

The cases presented in this review are proof that delaying therapy until the diagnosis is confirmed or even because not considering Naegleria fowleri infection can lead to a fulminant evolution with an unfortunate outcome. It is important that physicians who see patients with meningitis-specific symptoms of any cause should also consider Naegleria fowleri infection, especially in young people with a history of warm-season swimming in unhygienic, inadequately irrigated places, as prompt initiation of specific therapy may increase survival rates.

6. Limitations

Considering that the cases described did not follow a unique writing protocol, the lack of standardization of case presentation may lead to incomplete information about the cases included in the review. Moreover, the small number of cases reported at the global level may lead to misleading general conclusions, especially regarding the appropriate treatment for this type of patient. Another limitation can be considered the lack of a uniform sample of patients, due to the small number of cases; thus, conclusions about the exact cause of infection may not be clear and accurate. Moreover, the reasons why some patients are more susceptible to Naegleria fowleri infection have not yet been presented in the literature, especially since most of the patients were infected through contact with contaminated water with which many other people had previously come into contact.

Author Contributions

Conceptualization, C.R. and R.G.C.; methodology, A.O.; software, A.M.; validation, C.R., C.M.C. and M.R.R.; formal analysis, A.O.; investigation, C.R.; resources, A.M.; data curation, M.R.R.; writing—original draft preparation, C.R. and R.G.C.; writing—review and editing, M.M.L.; visualization, C.M.C.; supervision, M.M.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Matin, A. Primary amebic meningoencephalitis: A new emerging public health threat by Naegleria fowleri in Pakistan. J. Pharm. Res. Drug Des. 2017, 1, 1–3. [Google Scholar]
  2. Baqer, N.N.; Mohammed, A.S.; Al-Aboody, B.; Ismail, A.M. Genetic Detection of Amoebic Meningoencephalitis Causing by Naegleria Fowleri in Iraq: A Case Report. Iran J. Parasitol. 2023, 18, 408–413. [Google Scholar] [CrossRef] [PubMed]
  3. Hall, A.D.; Kumar, J.E.; Golba, C.E.; Luckett, K.M.; Bryant, W.K. Primary amebic meningoencephalitis: A review of Naegleria fowleri and analysis of successfully treated cases. Parasitol. Res. 2024, 123, 84. [Google Scholar] [CrossRef]
  4. Kemble, S.K.; Lynfield, R.; DeVries, A.S.; Drehner, D.M.; Pomputius, W.F., III; Beach, M.J.; Visvesvara, G.S.; da Silva, A.J.; Hill, V.R.; Yoder, J.S.; et al. Fatal Naegleria fowleri infection acquired in Minnesota: Possible expanded range of a deadly thermophilic organism. Clin. Infect. Dis. 2012, 54, 805–809. [Google Scholar] [CrossRef] [PubMed]
  5. Zeibig, E. Clinical Parasitology: A Practical Approach, 2nd ed.; Elsevier Saunders: St. Louis, MO, USA, 2013. [Google Scholar]
  6. Mahmud, R.; Ai Lian Lim, Y.; Amir, A. Medical Parasitology: A Textbook; Springer: Cham, Switzerland, 2017. [Google Scholar]
  7. Radulescu, S. Parazitologie Medicala; Editura ALL Education: București, Romania, 2000. [Google Scholar]
  8. Hong, K.W.; Jeong, J.H.; Byun, J.H.; Hong, S.H.; Ju, J.W.; Bae, I.G. Fatal Primary Amebic Meningoencephalitis due to Naegleria fowleri: The First Imported Case in Korea. Yonsei Med. J. 2023, 64, 641–645. [Google Scholar] [CrossRef]
  9. Gharpure, R.; Bliton, J.; Goodman, A.; Ali, I.K.M.; Yoder, J.; Cope, J.R. Epidemiology and Clinical Characteristics of Primary Amebic Meningoencephalitis Caused by Naegleria fowleri: A Global Review. Clin. Infect. Dis. 2021, 73, e19–e27. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  10. Saberi, R.; Seifi, Z.; Dodangeh, S.; Najafi, A.; Abdollah Hosseini, S.; Anvari, D.; Taghipour, A.; Norouzi, M.; Niyyati, M. A systematic literature review and meta-analysis on the global prevalence of Naegleria spp. in water sources. Transbound. Emerg. Dis. 2020, 67, 2389–2402. [Google Scholar] [CrossRef] [PubMed]
  11. Apley, J.; Clarke, S.K.; Roome, A.P.; Sandry, S.A.; Saygi, G.; Silk, B.; Warhurst, D.C. Primary amoebic meningoencephalitis in Britain. Br. Med. J. 1970, 1, 596–599. [Google Scholar] [CrossRef]
  12. Cain, A.R.; Wiley, P.F.; Brownell, B.; Warhurst, D.C. Primary amoebic meningoencephalitis. Arch. Dis. Child. 1981, 56, 140–143. [Google Scholar] [CrossRef]
  13. Stevens, A.R.; Shulman, S.T.; Lansen, T.A.; Cichon, M.J.; Willaert, E. Primary amoebic meningoencephalitis: A report of two cases and antibiotic and immunologic studies. J. Infect. Dis. 1981, 143, 193–199. [Google Scholar] [CrossRef]
  14. Barnett, N.D.; Kaplan, A.M.; Hopkin, R.J.; Saubolle, M.A.; Rudinsky, M.F. Primary amoebic meningoencephalitis with Naegleria fowleri: Clinical review. Pediatr. Neurol. 1996, 15, 230–234. [Google Scholar] [CrossRef]
  15. Sugita, Y.; Fujii, T.; Hayashi, I.; Aoki, T.; Yokoyama, T.; Morimatsu, M.; Fukuma, T.; Takamiya, Y. Primary amebic meningoencephalitis due to Naegleria fowleri: An autopsy case in Japan. Pathol. Int. 1999, 49, 468–470. [Google Scholar] [CrossRef]
  16. Jain, R.; Prabhakar, S.; Modi, M.; Bhatia, R.; Sehgal, R. Naegleria meningitis: A rare survival. Neurol. India 2002, 50, 470–472. [Google Scholar]
  17. Shenoy, S.; Wilson, G.; Prashanth, H.V.; Vidyalakshmi, K.; Dhanashree, B.; Bharath, R. Primary meningoencephalitis by Naegleria fowleri: First reported case from Mangalore, South India. J. Clin. Microbiol. 2002, 40, 309–310. [Google Scholar] [CrossRef]
  18. Centers for Disease Control and Prevention (CDC). Primary amebic meningoencephalitis-Georgia, 2002. Morb. Mortal Wkly. Rep. MMWR 2003, 52, 962–964. [Google Scholar]
  19. Cogo, P.E.; Scagli, M.; Gatti, S.; Rossetti, F.; Alaggio, R.; Laverda, A.M.; Zhou, L.; Xiao, L.; Visvesvara, G.S. Fatal Naegleria fowleri meningoencephalitis, Italy. Emerg. Infect. Dis. 2004, 10, 1835–1837. [Google Scholar] [CrossRef]
  20. Okuda, D.T.; Hanna, H.J.; Coons, S.W.; Bodensteiner, J.B. Naegleria fowleri hemorrhagic meningoencephalitis: Report of two fatalities in children. J. Child. Neurol. 2004, 19, 231–233. [Google Scholar] [CrossRef]
  21. Hebbar, S.; Bairy, I.; Bhaskaranand, N.; Upadhyaya, S.; Sarma, M.S.; Shetty, A.K. Fatal case of Naegleria fowleri meningo-encephalitis in an infant: Case report. Ann. Trop. Paediatr. 2005, 25, 223–226. [Google Scholar] [CrossRef]
  22. Vargas-Zepeda, J.; Gómez-Alcalá, A.V.; Vásquez-Morales, J.A.; Licea-Amaya, L.; De Jonckheere, J.F.; Lares-Villa, F. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch. Med. Res. 2005, 36, 83–86. [Google Scholar] [CrossRef]
  23. Petit, F.; Vilchez, V.; Torres, G.; Molina, O.; Dorfman, S.; Mora, E.; Cardozo, J. Meningoencefalitis amebiana primaria: Comunicacion de dos nuevos casos Venezolanos. Arq. de Neuro-Psiquiatria 2006, 64, 1043–1046. [Google Scholar] [CrossRef]
  24. Centers for Disease Control and Prevention (CDC). Primary amebic meningoencephalitis-Arizona, Florida, and Texas, 2007. Morb. Mortal Wkly. Rep. MMWR 2008, 57, 573–577. [Google Scholar]
  25. Gupta, N.; Bhaskar, H.; Duggal, S.; Ghalaut, P.S.; Kundra, S.; Arora, D.R. Primary amoebic meningoencephalitis: First reported case from Rohtak, North India. Braz. J. Infect. Dis. 2009, 13, 236–237. [Google Scholar] [CrossRef] [PubMed]
  26. Saleem, T.; Rabbani, M.; Jamil, B. Primary amoebic meningoencephalitis: Two new cases from Pakistan. Trop. Doct. 2009, 39, 242–243. [Google Scholar] [CrossRef]
  27. Shakoor, S.; Beg, M.A.; Mahmood, S.F.; Bandea, R.; Sriram, R.; Noman, F.; Ali, F.; Visvesvara, G.S.; Zafar, A. Primary amebic meningoencephalitis caused by Naegleria fowleri, Karachi, Pakistan. Emerg. Infect. Dis. 2011, 17, 258–261. [Google Scholar] [CrossRef] [PubMed]
  28. Khanna, V.; Khanna, R.; Hebbar, S.; Shashidhar, V.; Mundkar, S.; Munim, F.; Annamalai, K.; Nayak, D.; Mukhopadhayay, C. Primary Amoebic Meningoencephalitis in an Infant due to Naegleria fowleri. Case Rep. Neurol. Med. 2011, 2011, 782539. [Google Scholar] [CrossRef]
  29. Gautam, P.L.; Sharma, S.; Puri, S.; Kumar, R.; Midha, V.; Bansal, R. A rare case of survival from primary amebic meningoencephalitis. Indian J. Crit. Care Med. 2012, 16, 34–36. [Google Scholar] [CrossRef]
  30. Yoder, J.S.; Straif-Bourgeois, S.; Roy, S.L.; Moore, T.A.; Visvesvara, G.S.; Ratard, R.C.; Hill, V.R.; Wilson, J.D.; Linscott, A.J.; Crager, R.; et al. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin. Infect. Dis. 2012, 55, 79–85. [Google Scholar] [CrossRef]
  31. Movahedi, Z.; Shokrollahi, M.R.; Aghaali, M.; Heydari, H. Primary amoebic meningoencephalitis in an Iranian infant. Case Rep. Med. 2012, 2012, 782854. [Google Scholar] [CrossRef]
  32. Centers for Disease Control and Prevention (CDC). Notes from the field: Primary amebic meningoencephalitis associated with ritual nasal rinsing-St. Thomas, U.S. Virgin Islands, 2012. Morb. Mortal Wkly. Rep. MMWR 2013, 62, 903. [Google Scholar]
  33. Su, M.Y.; Lee, M.S.; Shyu, L.Y.; Lin, W.C.; Hsiao, P.C.; Wang, C.P.; Ji, D.D.; Chen, K.M.; Lai, S.C. A fatal case of Naegleria fowleri meningoencephalitis in Taiwan. Korean J. Parasitol. 2013, 51, 203–206. [Google Scholar] [CrossRef]
  34. Sood, A.; Chauhan, S.; Chandel, L.; Jaryal, S.C. Prompt diagnosis and extraordinary survival from Naegleria fowleri meningitis: A rare case report. Indian J. Med. Microbiol. 2014, 32, 193–196. [Google Scholar] [CrossRef]
  35. Shariq, A.; Afridi, F.I.; Farooqi, B.J.; Ahmed, S.; Hussain, A. Fatal primary meningoencephalitis caused by Naegleria fowleri. J. Coll. Physicians Surg. Pak. 2014, 24, 523–525. [Google Scholar]
  36. Booth, P.J.; Bodager, D.; Slade, T.A.; Jett, S. Primary Amebic Meningoencephalitis Associated with Hot Spring Exposure During International Travel—Seminole County, Florida, July 2014. Morb. Mortal Wkly. Rep. MMWR 2015, 64, 1226. [Google Scholar] [CrossRef]
  37. Cope, J.R.; Ratard, R.C.; Hill, V.R.; Sokol, T.; Causey, J.J.; Yoder, J.S.; Mirani, G.; Mull, B.; Mukerjee, K.A.; Narayanan, J.; et al. The first association of a primary amebic meningoencephalitis death with culturable Naegleria fowleri in tap water from a US treated public drinking water system. Clin. Infect. Dis. 2015, 60, 36–42. [Google Scholar] [CrossRef]
  38. Johnson, R.O.; Cope, J.R.; Moskowitz, M.; Kahler, A.; Hill, V.; Behrendt, K.; Molina, L.; Fullerton, K.E.; Beach, M.J. Notes from the Field: Primary Amebic Meningoencephalitis Associated with Exposure to Swimming Pool Water Supplied by an Overland Pipe—Inyo County, California, 2015. Morb. Mortal Wkly. Rep. MMWR 2016, 65, 424. [Google Scholar] [CrossRef]
  39. Cope, J.R.; Conrad, D.A.; Cohen, N.; Cotilla, M.; DaSilva, A.; Jackson, J.; Visvesvara, G.S. Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case. Clin. Infect. Dis. 2016, 62, 774–776. [Google Scholar] [CrossRef]
  40. Stubhaug, T.T.; Reiakvam, O.M.; Stensvold, C.R.; Hermansen, N.O.; Holberg-Petersen, M.; Antal, E.A.; Gaustad, K.; Førde, I.S.; Heger, B. Fatal primary amoebic meningoencephalitis in a Norwegian tourist returning from Thailand. JMM Case Rep. 2016, 3, e005042. [Google Scholar] [CrossRef]
  41. Stowe, R.C.; Pehlivan, D.; Friederich, K.E.; Lopez, M.A.; DiCarlo, S.M.; Boerwinkle, V.L. Primary Amebic Meningoencephalitis in Children: A Report of Two Fatal Cases and Review of the Literature. Pediatr. Neurol. 2017, 70, 75–79. [Google Scholar] [CrossRef]
  42. Cope, J.R.; Murphy, J.; Kahler, A.; Gorbett, D.G.; Ali, I.; Taylor, B.; Corbitt, L.; Roy, S.; Lee, N.; Roellig, D.; et al. Primary Amebic Meningoencephalitis Associated with Rafting on an Artificial Whitewater River: Case Report and Environmental Investigation. Clin. Infect. Dis. 2018, 66, 548–553. [Google Scholar] [CrossRef]
  43. Heggie, T.W.; Küpper, T. Surviving Naegleria fowleri infections: A successful case report and novel therapeutic approach. Travel. Med. Infect. Dis. 2017, 16, 49–51. [Google Scholar] [CrossRef]
  44. Ghanchi, N.K.; Jamil, B.; Khan, E.; Ansar, Z.; Samreen, A.; Zafar, A.; Hasan, Z. Case Series of Naegleria fowleri Primary Ameobic Meningoencephalitis from Karachi, Pakistan. Am. J. Trop. Med. Hyg. 2017, 97, 1600–1602. [Google Scholar] [CrossRef]
  45. Chomba, M.; Mucheleng’anga, L.A.; Fwoloshi, S.; Ngulube, J.; Mutengo, M.M. A case report: Primary amoebic meningoencephalitis in a young Zambian adult. BMC Infect. Dis. 2017, 17, 532. [Google Scholar] [CrossRef]
  46. Wang, Q.; Li, J.; Ji, J.; Yang, L.; Chen, L.; Zhou, R.; Yang, Y.; Zheng, H.; Yuan, J.; Li, L.; et al. A case of Naegleria fowleri related primary amoebic meningoencephalitis in China diagnosed by next-generation sequencing. BMC Infect. Dis. 2018, 18, 349. [Google Scholar] [CrossRef]
  47. Chen, M.; Ruan, W.; Zhang, L.; Hu, B.; Yang, X. Primary Amebic Meningoencephalitis: A Case Report. Korean J. Parasitol. 2019, 57, 291–294. [Google Scholar] [CrossRef]
  48. McLaughlin, A.; O’Gorman, T. A local case of fulminant primary amoebic meningoencephalitis due to Naegleria fowleri. Rural Remote Health 2019, 19, 4313. [Google Scholar] [CrossRef]
  49. Retana Moreira, L.; Zamora Rojas, L.; Grijalba Murillo, M.; Molina Castro, S.E.; Abrahams Sandí, E. Primary Amebic Meningoencephalitis Related to Groundwater in Costa Rica: Diagnostic Confirmation of Three Cases and Environmental Investigation. Pathogens 2020, 9, 629. [Google Scholar] [CrossRef]
  50. Huang, S.; Liang, X.; Han, Y.; Zhang, Y.; Li, X.; Yang, Z. A pediatric case of primary amoebic meningoencephalitis due to Naegleria fowleri diagnosed by next-generation sequencing of cerebrospinal fluid and blood samples. BMC Infect. Dis. 2021, 21, 1251. [Google Scholar] [CrossRef]
  51. Celik, Y.; Arslankoylu, A.E. A Newborn with Brain-Eating Ameba Infection. J. Trop. Pediatr. 2021, 67, fmaa100. [Google Scholar] [CrossRef]
  52. Anjum, S.K.; Mangrola, K.; Fitzpatrick, G.; Stockdale, K.; Matthias, L.; Ali, I.K.M.; Cope, J.R.; O’Laughlin, K.; Collins, S.; Beal, S.G.; et al. A case report of primary amebic meningoencephalitis in North Florida. ID Cases 2021, 25, e01208. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  53. Soontrapa, P.; Jitmuang, A.; Ruenchit, P.; Tiewcharoen, S.; Sarasombath, P.T.; Rattanabannakit, C. The First Molecular Genotyping of Naegleria fowleri Causing Primary Amebic Meningoencephalitis in Thailand with Epidemiology and Clinical Case Reviews. Front. Cell Infect. Microbiol. 2022, 12, 931546, Erratum in Front. Cell Infect. Microbiol. 2022, 12, 1021158. https://doi.org/10.3389/fcimb.2022.1021158. [Google Scholar] [CrossRef]
  54. Maloney, P.; Mowrer, C.; Jansen, L.; Karre, T.; Bedrnicek, J.; Obaro, S.K.; Iwen, P.C.; McCutchen, E.; Wetzel, C.; Frederick, J.; et al. Fatal Primary Amebic Meningoencephalitis in Nebraska: Case Report and Environmental Investigation, August 2022. Am. J. Trop. Med. Hyg. 2023, 109, 322–326. [Google Scholar] [CrossRef] [PubMed]
  55. Che, X.; He, Z.; Tung, T.H.; Xia, H.; Lu, Z. Diagnosis of primary amoebic meningoencephalitis by metagenomic next-generation sequencing: A case report. Open Life Sci. 2023, 18, 20220579. [Google Scholar] [CrossRef]
  56. Wang, F.; Shen, F.; Dai, W.; Zhao, J.; Chen, X.; Liu, J. A primary amoebic meningoencephalitis case associated with swimming in seawater. Parasitol. Res. 2023, 122, 2451–2452. [Google Scholar] [CrossRef]
  57. Wu, Q.; Chen, C.; Li, J.; Lian, X. Primary Amebic Meningoencephalitis Caused by Naegleria fowleri in China: A Case Report. Infect. Microbes. Dis. 2024, 6, 43–45. [Google Scholar] [CrossRef]
  58. Lin, L.; Luo, L.; Wu, M.; Chen, J.; Liao, Y.; Zhang, H. Utilizing metagenomic next-generation sequencing and phylogenetic analysis to identify a rare pediatric case of Naegleria fowleri infection presenting with fulminant myocarditis. Front. Microbiol. 2024, 15, 1463822. [Google Scholar] [CrossRef]
  59. Puthanpurayil, S.N.T.; Mukundan, A.; Nair, S.R.; John, A.P.; Thampi, M.R.; John, R.; Sehgal, R. Free-living amoebic encephalitis—Case series. Trop. Parasitol. 2024, 14, 108–112. [Google Scholar] [CrossRef]
  60. Lekkla, A.; Sutthikornchai, C.; Bovornkitti, S.; Sukthana, Y. Free-living ameba contamination in natural hot springs in Thailand. Southeast Asian J. Trop. Med. Public Health 2005, 36, 5–9. [Google Scholar]
  61. Güémez, A.; García, E. Primary Amoebic Meningoencephalitis by Naegleria fowleri: Pathogenesis and Treatments. Biomolecules 2021, 11, 1320. [Google Scholar] [CrossRef]
  62. Rajendran, K.; Anwar, A.; Khan, N.A.; Aslam, Z.; Raza Shah, M.; Siddiqui, R. Oleic Acid Coated Silver Nanoparticles Showed Better in Vitro Amoebicidal Effects against Naegleria fowleri than Amphotericin B. ACS Chem. Neurosci. 2020, 11, 2431–2437. [Google Scholar] [CrossRef]
  63. Fong, H.; Leid, Z.H.; Debnath, A. Approaches for Targeting Naegleria fowleri Using Nanoparticles and Artificial Peptides. Pathogens 2024, 13, 695. [Google Scholar] [CrossRef]
  64. Rajendran, K.; Anwar, A.; Khan, N.A.; Siddiqui, R. Brain-Eating Amoebae: Silver Nanoparticle Conjugation Enhanced Efficacy of Anti-Amoebic Drugs against Naegleria fowleri. ACS Chem. Neurosci. 2017, 8, 2626–2630. [Google Scholar] [CrossRef] [PubMed]
  65. Rajendran, K.; Anwar, A.; Khan, N.A.; Shah, M.R.; Siddiqui, R. trans-Cinnamic Acid Conjugated Gold Nanoparticles as Potent Therapeutics against Brain-Eating Amoeba Naegleria fowleri. ACS Chem. Neurosci. 2019, 10, 2692–2696. [Google Scholar] [CrossRef]
Figure 1. Geographical distribution of cases.
Figure 1. Geographical distribution of cases.
Jcm 14 00526 g001
Figure 2. Sources of infection.
Figure 2. Sources of infection.
Jcm 14 00526 g002
Figure 3. Mortality rate.
Figure 3. Mortality rate.
Jcm 14 00526 g003
Table 1. Characteristics of cases included in the review.
Table 1. Characteristics of cases included in the review.
Author, and YearCountryNumber of CasesSex and AgeCausesOnset SymptomsDiagnostic TestMedical History
J. Apley et al. [11]UK3 casesCase 1—male, 2 years.
Case 2—male, 6 years.
Case 3—male, 4 years
Case 1–3—playing with contaminated water (muddied puddle)C1–C3: anorexia, irritability, sore throat, vomiting, headache, fever, neck painsCultured/wet mount from cerebrospinal fluid (CSF)C3: 2 days before admission, he had a booster dose of diphtheria pertussis and tetanus vaccine
A.R. Cain et al., 1981 [12]UK1 caseFemale, 11 yearsContaminated pool water (indoor pool fed by natural warm
spring water)
Headache
Fever
Vomiting
Blurred vision
CSFHealthy
AR Stevens et al., 1981 [13]USA2 casesCase 1—male, 14 years
Case 2—male, 10 years
Case 1 and 2—swimming in contaminated water (freshwater lake)C1: headache, fever, malaise
C2: headache, lethargy, anorexia
CSFHealthy
N.D.P. Barnett et al., 1996 [14]USA2 caseCase 1—Female, 9 years
Case 2—male, 8 month
Case 1—Swimming in contaminated water (ditch)
Case 2—baptized in contaminated water
C1: Headache
Emesis
C2: emesis, fever
C1 and C2: cranial CT scan, CSFHealthy
Y. Sugita et al., 1999 [15]Japan1 caseFemale, 25 yearsNo dataHeadache
High fever
CSF, cranial CT scanHealthy
Jain et al., 2002 [16]India1 caseFemale, 26 yearsNo dataHeadache
Fever
Vomiting
Altered sensorium
CSFHealthy
S Shenoy et al., 2002 [17]India1 caseMale, 5-month-oldContaminated bath waterFever
Vomiting
Seizures
CSFHealthy
Centers for Disease Control and Prevention (CDC), 2003 [18]USA1 caseMale, 11 yearsSwimming in contaminated water (local river)Headache
Emesis
CSF and cranial MRIHealthy
P.E. Cogo et al., 2004 [19]Italy1 caseMale, 9 yearsSwimming in contaminated river waterFever
Headache
CSF and cranial CTHealthy
D.T. Okuda et al., 2004 [20]USA2 casesCase 1—male, 5 years
Case 2—male, 5 years
Case 1—no data
Case 2—contaminated water (bath water)
C1: Headache, neck stiffness
C2: fever, progressive lethargy
CSF and cranial MRIHealthy
S. Hebbar et al., 2005 [21]India1 caseMale, 6 monthsContaminated bath waterSeizures
Fever
Lethargy
Altered sensorium
CSFHealthy
J. Vargas-Zepada el al, 2005 [22]Mexic1 caseMale, 10 yearsSwimming in contaminated water (irrigation canal)Severe headache
Vomiting
Fever
CSF, cranial CTHealthy
F. Petit et al., 2006 [23]Venezuela2 casesCase 1—male, 10 years
Case 2—male, 23 years
Swimming in contaminated water reservoirC1: Headache
Fever
Vomiting
C2: headache, fever, vomiting, drowsiness, behavioral disturbances
CSFHealthy
CDC, 2008 [24]USA6 casesCase 1—male, 14 years
Case 2—male, 14 years
Case 3—male, 11 years
Case 4—male, 12 years
Case 5—male, 22 years
Case 6—male, 10 years
Case 1, 3, 4, 5— swimming in contaminated lake water
Case 2—swimming in multiple drainage ditches, canals, and apartment pool
Case 6—swimming in a private water sports facility
C1: severe headache, stiff neck, fever
C2: ear pressure, severe headache, vomiting
C3: headache, fever, nausea, vomiting, confusion
C4: fever, lethargy, confusion
C5: altered mental status, severe headache
C6: body aches, high fever, nausea, vomiting, fainting
CSFHealthy
N. Gupta et al., 2009 [25]India1 caseMale, 20 yearsNo association with contaminated waterFever
Headache
Loss of vision
Hearing loss
Slurring of speech
Difficulty in swallowing
Retention of urine
CSF, cranial CT scanTuberculosis,
diabetes mellitus, hypertension, and acute leukemic leukemia.
T. Saleem et al., 2009 [26]Pakistan2 casesCase 1—male, 24 years
Case 2—male, 30 years
Case 1 and 2—swimming in contaminated waterC1: high fever, headache, vomiting
C2: high fever, headache, agitation
CSF and cranial CT scanHealthy
S. Shakoor et al., 2011 [27]Pakistan13 cases12/13 were male, mean age 31.0 ± 15.33 yearsNo exact dataFever
Headache
Seizures
CSFHealthy
Khanna et al., 2011 [28]India1 caseMale, 5 monthsNo dataFever
Decreases breastfeeding
Vomiting
Abnormal body movements
CSFHealthy
Gautam et al., 2012 [29]India1 caseMale, 73 yearsNo dataFever
Neck pain
Seizures
Altered sensorium
CSF and cranial CT scanType II diabetes mellitus, diabetic nephropathy, coronary artery disease (postangioplasty in 2005), head injury (9 years back), and CSF (cerebrospinal fluid) rhinorrhea
S.K. Kemble et al., 2012 [4]USA1 caseFemale, 7 yearsSwimming in contaminated lake waterHeadache
Abdominal pain
Neck soreness
CSF, PCR, and CT scanHealthy
J.S. Yoder et al., 2012 [30]USA2 casesCase 1—male, 28 years
Case 2—female, 51 years
Contaminated tap water utilized for sinus IrrigationC1: severe headache, neck stiffness, back pain, vomiting
C2: altered mental status, nausea, vomiting, poor appetite, fatigue, high fever
C1: CSF, cranial CT scan, PCR
C2: CSF
C1: migraine
C2: Healthy
Z. Movahedi et al., 2012 [31]Iran1 caseMale, 5-month-oldNo dataFever
Eye gaze
Chills
CSF and cranial CT scanHealthy
CDC, 2013 [32]USA1 caseMale, 47 yearsContaminated tap water used for daily household activities and for ablutionHeadache
Fever
Confusion
Agitation
CSF and PCRHealthy
M.Y. Su et al., 2013 [33]Taiwan1 caseMale, 75 yearsSwimming in contaminated pool water (hot springs)Headache
Fever
Right arm myoclonic seizures
CSF, MRI of the brain, cranial CT scanHealthy
A. Sood et al., 2014 [34]India1 caseMale, 6 yearsPlaying with contaminated water (cement tank)Fever
Headache
Altered sensorium
CSFHealthy
A. Shariq et al., 2014 [35]Pakistan1 caseMale, 42 yearsUsing contaminated waterFever
Vomiting
Loose stools
Behavioral disturbances
CSFHealthy
P.J. Booth et al., 2015 [36]USA1 caseMale, 11 yearsSwimming in contaminated pool water (resort hot springs)Headache
Fever
Stiff neck
Nausea
Vomiting
CSFHealthy
J.R. Cope et al., 2015 [37]USA1 caseMale, 4 yearsPlaying with contaminated pool waterVomiting
Severe headache
Diarrhea
Poor oral intake
CSF and cranial CT scanHealthy
R.O. Johnson et al., 2016 [38]USA1 caseFemale, 21 yearsSwimming in contaminated spring waterHeadache
Nausea
Vomiting
CSFHealthy
J.R. Cope et al., 2016 [39]USA2 casesCase 1—male, 12 years
Case 2—male, 8 years
Case 1—contaminated stagnant rainwater
Case 2—contaminated river water
C1: headache, weakness, vomiting, fever, altered mental status C2: fever, headache, chills, nausea, vomiting, altered mental statusC1: CSF, cranial CT scan, PCR
C2: CSF
Healthy
T.T. Stubhaug et al., 2016 [40]Norway1 caseFemale, 71 yearsContaminated tap waterNausea, vomiting, fever, exhaustionCSF, cranial CT scanHealthy
R.C. Stowe et al., 2017 [41]USA2 casesCase 1—male, 5 years
Case 2—male, 14 years
Case 1 and 2—swimming in contaminated waterC1: fever, altered mental status, seizures
C2: generalized muscle weakness, fever
C1: CSF, cranial CT, brain MRI
C2: CSF, cranial CT
Healthy
J.R. Cope et al., 2017 [42]USA1 caseFemale, 18 yearsSwimming in contaminated waterHeadache
Fever
Lethargy
CSF, cranial CT scanHealthy
T.W. Heggie et al., 2017 [43]USA1 caseFemale, 12 yearsSwimming in contaminated lake waterVomiting
Fever
Headache
CSFHealthy
N.K. Ghanchi et al., 2017 [44]Pakistan19 cases84% male, median age 28 years (16/19)No exact dataFever (63%)
Altered consciousness (53%)
Headache (32%)
Seizures (21)
Disorientation (10%)
CSF and PCRHealthy
M. Chomba et al., 2017 [45]Zambia1 caseMale, 24 yearsSwimming in contaminated river waterSeizures
Fever
CSF, cranial CTHealthy
Q. Wang et al., 2018 [46]China1 caseMale, 42 yearsContaminated waterFever
Headache
CSF, cranial CTHealthy
M. Chen et al., 2019 [47]China1 caseMale, 43 yearsSwimming in contaminated pool waterHeadache
Fever
Myalgia
Fatigue
CSF, cranial CTHealthy
A. McLaughlin et al., 2019 [48]Australia1 caseMale, 56 yearsSwimming in contaminated water/irrigation of nostrilsHeadache
Photophobia
Nausea
Vomiting
Neck stiffness
CSF, cranial CTNo data
L.R. Moreira et al., 2020 [49]Costa Rica3 casesCase 1—male, 15 years
Case 2—female, 5 years
Case 3—male, 1 year
Case 1 and 2—contaminated pool water (hot spring resort)
Case 3—contaminated bath water
C1: general discomfort, severe headache, nausea, vomiting
C2: lower limb pain, spasticity, hyperreflexia, walking difficulty, headache, vomiting, fever
C3: fever, drowsiness, altered state of consciousness.
C1: no data
C2 and C3: CSF
Healthy
S. Huang et al., 2021 [50]China1 caseMale, 8 yearsSwimming in contaminated waterHeadache
Vomiting
Fever
Disturbance of consciousness
CSF, cranial CT scan, head and neck MRINo data
Y. Celik et al., 2021 [51]Turkey1 caseMale, 11 days oldContaminated bath waterIrritability
Inability to suck
Fever
CSF, cranial MRI, PCRHealthy
S.K. Anjum et al., 2021 [52]USA1 caseMale, 13 yearsSwimming in contaminated water (water park)Headache
Fever
Intractable emesis
CSF, cranial CT scan, brain MRI, PCRHistory of headache
P. Soontrapa et al., 2022 [53]Thailand1 caseFemale, 40 yearsContaminated water (she poured water from a waterfall on her
head and face)
Severe headache
High fever
CSF, cranial CT scanNo data
P. Maloney et al., 2022 [54]USA1 caseMale, 8 yearsSwimming in contaminated river waterFever
Altered mental status
Malaise
Headache
Fatigue
Decreased appetite
CSF, cranial CT scanHealthy
X. Che et al., 2023 [55]China1 caseMale, 38 yearsNo exact dataFever
Headache
Disturbance of consciousness
CSF and cranial CT scanNo data
K.W. Hong et al., 2023 [8]Korea1 caseMale, 52 yearsNo exact dataHeadache
Fever
CSF and cranial CT scanNo data
N.N. Baqer et al., 2023 [2]Iraq1 caseFemale, 18 yearsContaminated river waterFever
Headache
Stiff neck
CSF, PCR, cranial CT scanWeight-loss and malnutrition
F. Wang et al., 2023 [56]China1 caseMale, 62 yearsContaminated water (the patient was a fisherman)Vomiting
Headache
Behavior change
CSF and cranial CT scanNo data
Q. Wu et al., 2024 [57]China1 caseMale, 42 yearsHe drank tea and was washed by his mother with spring water.High feverCSF, cranial CT scanThe patient was bed-ridden due to a disability caused by burns
L. Lin et al., 2024 [58]China1 caseFemale, 6 yearSwimming in contaminated pool waterFever
Headache
Vomiting
Lethargy
Metagenomic next-generation sequencing, CSF, PCR, cranial CT scanHealthy
S.N. Puthanpurayil et al., 2024 [59]India1 caseMale, 36 yearsContaminated tap water (nasal irrigation)Seizures
Altered sensorium
Headache
Nausea
Photophobia
High fever
CSFHealthy, 15-year-old corrected surgically nasal bone fracture
Blood samples for biochemistry and hemogram were taken from all patients.
Table 2. Evolution and treatment of the patients included in the review.
Table 2. Evolution and treatment of the patients included in the review.
AuthorTimeline Between Exposure and Onset of SymptomsTimeline Between Onset of Symptoms and Presentation to HospitalAntibiotic TreatmentDays of HospitalizationEvolution
J. Apley et al. [11]C1: 2 days
C2: 9 days
C3: 13 days
C1: One day before admission
C2: on the morning of admission
C3: on the morning of admission
Case 1—Sulfadiazine, Penicilina, Ampicilina, Amphotericin B
Case 2—Sulfadiazine, Amphotericin B
Case 3—Sulfadiazine, Amphotericin B
Amphotericin 0.25 mg/kg/day iv. to 1 mg/kg/day iv
Sulphadiazine 750 mg/6 h
Case 1—16 days;
Case 2—18 days;
Case 3—24 days
Case 1—died;
Case 2—cured;
Case 3—cured
A.R. Cain et al. [12]6 days3 daysPenicillin, Sulfadimidine, Chloramphenicol, Sulfadiazine, Metronidazole, Amphotericin B.
Amphotericin B 0.5 mg to 0.6 mg/kg/day/iv
Amphotericin B 0.1 mg through an intraventricular catheter
4 daysDied
A.R. Stevens et al. [13]C1: 3 weeks before
C2: several days before
C1: 2 days
C2: on the day of admission into the hospital
Case 1—Penicillin G 3 g/4 h, Amphotericin B 10 mg/day iv and 0.05 mg/day intrathecally, Miconazole 200 mg/day iv and intrathecally 20 mg/day
Case 2—Penicillin 1.25 million units/6 h iv, Amphotericin B 1 mg/kg/day iv and intraventricular 0.1 mg
Case 1 and 2—5 daysCase 1 and 2—died
N.D.P. Barnett et al. [14]C1: The day after exposure
C2: soon after baptized
C1: 2 days
C2: 24 h
C1 and C2: Cefuroxime, Acyclovir
No data regarding doses
C1: 4 days
C2: 3 days
C1 and C2: Died
Y. Sugita et al. [15]No data2 daysNo data8 daysDied
Jain et al. [16]No data10 daysAmphotericin B 1 mg/kg/day iv
Rifampicin 450 mg/day po
Ornidazole 500 mg/8 h
28 daysCured
S. Shenoy et al. [17]No data1 weekAmphotericin B 0.6 mg/kg/day iv
Ceftriaxone 100 mg/kg/day po
2 daysDied
Centers for Disease Control and Prevention (CDC) [18]No data2 daysAmphotericin B, Rifampicin, Ketoconazole4 daysDied
P.E. Cogo et al. [19]10 days1 dayCeftriaxone, Acyclovir 0.35 g/kg/6 h4 daysDied
D.T. Okuda et al. [20]No dataC1: no data
C2: 3 days
Case 1—no data
Case 2—empiric antibiotic
Case 1—48 h
Case 2—no data
Case 1—died
Case 2—died
S. Hebbar et al. [21]No data3 daysAmphotericin B, Chloramphenicol and Metronidazole10 hDied
J. Vargas-Zepada et al. [22]One week before admission into the hospitalOn the day of admission into the hospitalCeftriaxone 100 mg/kg/8 h iv, Rifampicin 10 mg/kg/24 h po and Amphotericin B 0.25 mg/kg/24 h iv (daily 0.25 mg/kg increasing dosage up to 1 mg/kg/day), Fluconazole 10 mg/kg/24 h iv23 daysCured
F. Petit et al. [23]C1: 5 days
C2: no data
C1: one day before admission into the hospital
C2: 4 days before admission into the hospital
Case 1—Amphotericin B
Case 2—no data
Case 1—3 days
Case 2—2 days
Case 1—died
Case 1—died
CDC [24]C1: 7 days
C2: 2 weeks
C3: 6 days
C4: weeks
C5: 7 days
C6: 8–15 days
C1: 2 days
C2: 2 days
C3: 4 days
C4: 6 days
C5: 2 days
C6: 3 days
Case 1—no data
Case 2—no data
Case 3—Amphotericin B, Fluconazole, Ceftriaxone, Azithromycin, Rifampicin
Case 4—Amphotericin B, Rifampicin, Azithromycin
Case 5—no data
Case 6—Amphotericin B, Rifampicin, Azithromycin, Fluconazole
Case 1—2 days
Case 2—no data
Case 3—3 days
Case 4—5 days
Case 5—5 days
Case 6—3 days
Case 1—died
Case 2—died
Case 3—died
Case 4—died
Case 5—died
Case 6—died
N Gupta et al. [25]No data2 daysCeftriaxone, Amikacin, Amphotericin B, RifampicinNo exact dataDied
T. Saleem et al. [26]No dataC1: 2 days
C2: 3 days
Case 1—Ceftriaxone, Acyclovir, Vancomycin, Meropenem, Amphotericin B, Fluconazole, Rifampicin
Case 2—Acyclovir, Ceftriaxone, Meropenem, Vancomycin, Amphotericin B, Fluconazole
Case 1—6 days
Case 2—8 days
Case 1—died
Case 2—died
S. Shakoor et al. [27]No dataMean ±SD: 2.5 ± 1.19 daysAmphotericin B (1.5 mg/kg/day/iv), Rifampin (600 mg/day), Fluconazole or Itraconazole6.38 ± 3.15 daysDied
Khanna et al. [28]No data2 daysCeftriaxone 250 mg TID and iv, Amikacin 50 mg BD
Amphotericin B 3 mg iv, ceftazidime 300 mg iv
2 daysDied
Gautam et al. [29]No data3 daysAmphotericin B (1 mg/kg/day) and oral Rifampicin (600 mg OD)10 daysCured
S.K. Kemble et al. [4]2 weeks5 daysPenicillin, Ceftriaxone, Vancomycin4 daysDied
J.S. Yoder et al. [30]No dataC1: 1 day
C2: 3 days
Case 1—Ceftriaxone, Linezolid, Acyclovir, Amphotericin B, Rifampin
Case 2—no data
Case 1—4 days
Case 2—5 days
Case 1—died
Case 2—died
Z. Movahedi et al. [31]No data3 daysRifampin 10 mg/kg orally daily, Amphotericin B 1 mg/kg/day, Ceftriaxone, VancomycinNo exact dataCured
CDC [32]No exact dataNo exact dataNo data34 daysDied
M.Y. Su et al. [33]No dataNo dataIntravenous amphotericin B 50 mg/day21 daysDied
A. Sood et al. [34]No dataNo dataIntravenous amphotericin B (1 mg/kg), intravenous Fluconazole (8 mg/kg), and oral Rifampicin (10 mg/kg) for 21 days21 daysCured
A. Shariq et al. [35]No data2 daysAmphotericin-B 1.5 mg/kg iv divided in two divided
doses daily plus 1.5 mg/day intrathecal
3 daysDied
P.J. Booth et al. [36]4 days2 daysNo data4 daysDied
J.R. Cope et al. [37]10 days1 dayVancomycin, Ceftriaxone5 daysDied
R.O. Johnson et al. [38]2 weeks1 dayNo data3 daysDied
J.R. Cope et al. [39]No dataC1: 2 days
C2: 5 days
Case 1—Acyclovir, Amphotericin B, Fluconazole, Rifampin, Vancomycin, Ceftriaxone, Azithromycin, Miltefosine
Case 2—Miltefosine
Case 1—16 days
Case 2—85 days
Case 1—died
Case 2—cured, but remains with profound persistent mental disability
T.T. Stubhaug et al. [40]Approx. 12 days2 daysMeropenem, Vancomicin, GentamicinNo exact dataDied
R.C. Stowe et al. [41]C1: 8 days
C2: 8 days
C1: 5 days
C2: 3 days
Case 1—Azithromycin, Rifampin, Amphotericin B, Fluconazole, Miltefosine
Case 2—Vancomycin, Ceftriaxone, Fluconazole, Azithromycin, Rifampin, Amphotericin, Miltefosine
Case 1—2 days
Case 2—4 days
Case 1—died
Case 2—died
J.R. Cope et al. [42]Approx. 10 days3 daysAmphotericin B, Fluconazole, Azithromycin, Rifampin3 daysDied
T.W. Heggie et al. [43]Few days2 daysAmphotericin B, Rifampin, Fluconazole, Dexamethasone, Azithromycin, Miltefosine55 daysCured
N.K. Ghanchi et al., 2017 [44]No data2–3 daysTherapeutic protocol for primary amoebic meningoencephalitis3–4 days18/19 died
M. Chomba et al., 2017 [45]2 days1 dayAmphotericin B 50 mg IV, Ceftriaxone 2 g/day iv8 daysDied
Q. Wang et al., 2018 [46]1 week1 dayCeftriaxone 2 g, Meropenem, Linezolid, Amphotericin B at 50 mg/day, Fluconazole 0.4 g/day15 daysDied
M. Chen et al. [47]No exact data2 daysAmphotericin B, Fluconazole15 daysDied
A. McLaughlin et al. [48]No exact data36 hIntrathecal amphotericin 1.5 mg daily, amphotericin 50 mg/12 h IV, Rifampicin 600 mg IV daily, azithromycin 500 mg IV daily, Fluconazole 800 mg IV daily3 daysDied
L.R. Moreira et al. [49]C1: 7 days
C2: 2 days
C3: no exact data
C1: no data
C2: 1 day
C3: 3 days
Case 1—no data
Case 2—Amphotericin B
Case 3—no data
Case 1—6 days
Case 2—28 days
Case 3—1 day
Case 1—died
Case 2—cured
Case 3—died
S. Huang et al. [50]3 days1 dayMeropenem, Vancomycin, Ceftriaxone24 daysDied
Y. Celik et al. [51]4 days2 daysAmpicillin, Cefotaxime, Vancomycin, Meropenem, Amphotericin B, Fluconazole, Rifampicin, AzithromycinApprox. 4 monthsDied
S.K. Anjum et al. [52]3 daysOn the day of admission into the hospitalCeftriaxone, Acyclovir, Vancomycin, Miltefosine, Amphotericin B, Fluconazole, Rifampin, Azithromycin5 daysDied
P. Soontrapa et al. [53]3 days1 dayCeftriaxone, Doxycycline, Amphotericin B, Rifampicin, Fluconazole, Azithromycin5 daysDied
P. Maloney et al. [54]5 days3 daysAmphotericin B, Azithromycin, Fluconazole, Rifampin28 hDied
X. Che et al. [55]No data2 daysPenicillin, Ceftriaxone4 daysDied
K.W. Hong et al. [8]No exact data3 daysVancomycin, Ceftriaxone, Ampicillin, Amphotericin B, Fluconazole, Azithromycin, Rifampicin13 daysDied
N.N. Baqer et al. [2]No exact data2 daysNo treatmentNo dataDied
F. Wang et al. [56]No exact data3 daysNo exact data3 daysDied
Q. Wu et al. [57]Approx. 1 weekNo dataMeropenem (2000 mg/8 h), Metronidazole (500 mg/8 h), Fluconazole (800 mg/day), Piperacillin-Tazobactam2 daysDied
L Lin et al. [58]7 days14 hCefaclor, Meropenem, Acyclovir, Vancomycin, Amphotericin B, Rifampicin80 hDied
S.N. Puthanpurayil et al. [59]No data2 daysCeftriaxone
Acyclovir
No exact dataDied
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rîpă, C.; Cobzaru, R.G.; Rîpă, M.R.; Maștaleru, A.; Oancea, A.; Cumpăt, C.M.; Leon, M.M. Naegleria fowleri Infections: Bridging Clinical Observations and Epidemiological Insights. J. Clin. Med. 2025, 14, 526. https://doi.org/10.3390/jcm14020526

AMA Style

Rîpă C, Cobzaru RG, Rîpă MR, Maștaleru A, Oancea A, Cumpăt CM, Leon MM. Naegleria fowleri Infections: Bridging Clinical Observations and Epidemiological Insights. Journal of Clinical Medicine. 2025; 14(2):526. https://doi.org/10.3390/jcm14020526

Chicago/Turabian Style

Rîpă, Carmen, Roxana Gabriela Cobzaru, Miruna Raluca Rîpă, Alexandra Maștaleru, Andra Oancea, Carmen Marinela Cumpăt, and Maria Magdalena Leon. 2025. "Naegleria fowleri Infections: Bridging Clinical Observations and Epidemiological Insights" Journal of Clinical Medicine 14, no. 2: 526. https://doi.org/10.3390/jcm14020526

APA Style

Rîpă, C., Cobzaru, R. G., Rîpă, M. R., Maștaleru, A., Oancea, A., Cumpăt, C. M., & Leon, M. M. (2025). Naegleria fowleri Infections: Bridging Clinical Observations and Epidemiological Insights. Journal of Clinical Medicine, 14(2), 526. https://doi.org/10.3390/jcm14020526

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop